A House committee has approved sweeping transportation legislation that would, for the first time, direct federal agencies to develop evidence-based impairment standards for cannabis and other drugs - a long-overdue policy step that carries real consequences for licensed cannabis operators, compliance professionals, and the broader debate over workforce drug testing. The House Transportation and Infrastructure Committee voted 61-2 to advance the BUILD for America's 250th Act, a 1,000-plus-page bill covering roads, bridges, rail, and highway programs. Tucked inside are provisions that could reshape how federal authorities treat cannabis impairment on the road and in safety-sensitive occupations for years to come.
What the Bill Actually Requires - and What It Doesn't Yet Do
Let's be precise about what this legislation does. It does not establish impairment standards. It directs the secretary of transportation, in collaboration with other relevant federal agencies, to study the effects of "intoxicating cannabinoids and polysubstance impairment" on driving, analyze detection and reduction measures, and then propose evidence-based standards. A report to Congress must follow. That's a study mandate, not a regulatory rule - an important distinction that compliance teams at multi-state operators and cannabis companies should register clearly.
The bill also directs creation of a national drug-involved crash data collection system. That system would collect standardized toxicology data from states for fatal and serious injury crashes, link crash records with medical, coroner, hospital, and EMS data, and establish model protocols for specimen collection, testing, and reporting. The Department of Transportation could award grants to states for pilot programs, and $110 million is allocated across fiscal years 2027-2031. Privacy protections would require all public-facing data to be deidentified before release. Separately, the National Highway Traffic Safety Administration would be required to report on the status of collaborative research into impaired driving prevention technology.
One notable editorial choice in the legislation: a manager's amendment replaced the word "marijuana" throughout the relevant section with "intoxicating cannabinoids." That's not just semantic housekeeping. It reflects a deliberate move to align federal legislative language with how the industry and the scientific community increasingly discuss cannabis compounds - a recognition that THC is one actor among many, and that polysubstance impairment involving cannabis, opioids, alcohol, or prescription drugs presents a different evidentiary challenge than single-substance testing.
The Compliance Gap This Bill Is Trying to Close
The absence of a validated, federally recognized impairment standard for cannabis has been one of the most stubborn regulatory problems in the industry since adult-use legalization began spreading through states. Unlike blood alcohol content, where decades of research produced a legal threshold most jurisdictions accept, there is no equivalent standard for THC. Detection windows for cannabis metabolites in blood, urine, and saliva don't map cleanly onto actual impairment - a fact that creates serious complications for employers, law enforcement, prosecutors, and policymakers alike.
Here's the catch for dispensaries and cannabis businesses specifically: without a reliable federal impairment standard, the policy vacuum gets filled by blunt instruments - zero-tolerance workplace drug testing, per se drugged driving laws in certain states, and the kind of broad prohibitions the Department of Transportation reaffirmed just days before the committee vote. DOT issued guidance this month reiterating that truck drivers, airline pilots, and other safety-sensitive workers cannot use medical marijuana without consequence, regardless of the Trump administration's move to reschedule cannabis. "Marijuana use is not compatible with safety-sensitive functions," the agency stated plainly. Medical review officers were told explicitly that a lab-confirmed cannabis positive cannot be marked negative even when an employee claims state-licensed medical marijuana use - because state-dispensed medical cannabis still does not constitute an FDA-approved drug, even post-rescheduling.
That's a significant operational reality for cannabis businesses that employ workers who hold commercial driver's licenses or other safety-sensitive credentials, and it reflects just how far the regulatory infrastructure still lags behind both state-level legalization and federal scheduling reform.
Why Cannabis Operators Should Pay Attention to Infrastructure Legislation
This isn't the kind of bill that typically lands on a dispensary compliance officer's reading list. But it should. The development of federally recognized impairment standards - however far off that outcome may be - would have direct implications for how cannabis businesses manage workforce compliance, how employee drug testing programs are structured, and potentially how product labeling and consumer safety disclosures evolve under pressure from federal agencies.
Multi-state operators in particular have spent years managing a patchwork of state-level impaired driving laws alongside federal DOT drug testing requirements for any employees in safety-sensitive roles. A nationally standardized toxicology data system - with $110 million behind it and a mandate to link crash data across state lines - would eventually generate the evidentiary record that regulators need to set defensible thresholds. Whether those thresholds prove favorable or restrictive for cannabis users in the workforce is an open question. But the direction of travel is clear: the federal government is building the data architecture to justify a standard, which means a standard is coming, on a timeline measured in years rather than decades.
For cannabis retailers and brands, that has downstream implications. Consumer safety messaging, packaging disclosures, and responsible-use guidance - areas where the industry has largely self-regulated - may eventually face federal benchmarks tied to whatever impairment thresholds emerge from this process. That's not imminent. But operators who engage in long-range compliance planning would be shortsighted to ignore the scaffolding being assembled here.
The Political Moment Around This Bill
The bill passed committee 61-2, with bipartisan backing from chair Sam Graves (R-MO) and ranking member Rick Larsen (D-WA). Graves has indicated he wants to move it to the House floor before the current federal transportation authorization expires September 30. That is a tight window for a 1,000-page bill, and the Senate will have its own views. Large transportation reauthorizations historically go through multiple rounds of negotiation; the cannabis impairment provisions are unlikely to be the most contested element of a bill covering roads, bridges, and rail funding.
What's striking is the political context surrounding it. Last week, Republican lawmakers joined anti-marijuana advocacy groups to push for a carve-out ensuring that safety-sensitive workers continue to be tested and disciplined for cannabis use - a signal that even as rescheduling proceeds, enforcement posture around cannabis in the workplace is not softening. Transportation Secretary Sean Duffy has been openly skeptical of cannabis policy liberalization. The BUILD Act's impairment study mandate exists in that environment, which means the standards that eventually emerge from any federal research effort will be shaped by an agency that, at least under current leadership, is not inclined toward permissive interpretations.
To put it plainly: the cannabis industry has long argued that the absence of a science-based impairment standard is unfair to consumers and workers. That argument now has a legislative vehicle. Whether the standards produced by that vehicle will reflect the nuance the industry is hoping for remains entirely to be seen.
